Who is Sanofi?
Sanofi is a worldwide research, development, marketing, and manufacturing company who primarily manufacturers prescription and over-the-counter medications. The company produces products to help individuals who are battling a variety of health conditions including diabetes, cancer, thrombosis, and cardiovascular conditions. The company is also one of the world’s largest vaccine producers. Before Sanofi merged with Aventis they were their own subsidiary called Elf Aquitaine, a French company. In 1999, Sanofi merged with Synthélabo to form Sanofi-Synthélabo, becoming one of France’s largest pharmaceutical groups. At the time of the merger, Sanofi-Synthélabo’s was located in Paris, France, and was focused primarily on the production of pharmaceuticals.
In 1999, a German corporation named Hoechst Marion Roussel merged with a French company named Rhône-Poulenc to form Aventis. The merged corporation was located in Schiltigheim, France. This new company focused on vaccines, animal nutrition, and pharmaceuticals. Later in 2004, Sanofi-Synthélabo acquired Aventis and formed Sanofi-Aventis.
In February 2015, Sanofi announced Olivier Brandicourt will replace Chris Viehbacher as its next chief executive officer. Brandicourt, who has spent previous years as head of Bayer and Pfizer, is seen by many as the perfect person to deal with the commercial challenges that are sure to plague the company over the next several years. Despite issues with local regulators and what some have called a “make-or-break pipeline,” the company believes it can bring in $38 billion in the next five years.
The company also affirms they will continue to work with their partners to “protect the health, enhance life, provide hope, and respond to the potential healthcare needs of 7 billion people around the world.” Their goal is to continue to commit their expertise and energies to helping patients by providing therapeutic solutions that work.
Facts about Sanofi
- Name changed from Sanofi-Synthélabo to Sanofi in 2011
- In March 2014 Sanofi joined the bidding for Merck & Co.’s over-the-counter health-products unit
- In October 2014 the board of Sanofi fired CEO Chris Viehbacher
- Sanofi’s common products include Auvi-Q used to treat life-threatening allergic reactions
- Sanofi is headquartered in Paris, France
- Sanofi’s United State’s headquarters is in Bridgewater, New Jersey
- Sanofi employs more than 110,000 people worldwide and 16,000 people in the United States.
History of Sanofi
Sanofi, which is now one of the largest pharmaceutical companies in the world, began more than 100 years ago when a number of smaller businesses merged. Over the years there have been a series of partnerships and acquisitions expanding the company into more than 100 countries, including the United Kingdom, United States, Canada, Germany, Russia, Spain, Australia, Argentina and China. But the company had humble beginnings, originating in 1718 when a group of pharmacists established Laboratoires Midy. This company merged with another French company to become Clin Midy group, which was later acquired by Sanofi. In 1999, this company later merged with another company called Synthélabo. In 2004, Sanofi-Synthélabo’s offered to takeover Aventis. There were some heated negotiations, but the acquisition was successful. Later the company updated their name to Sanofi-Aventis. In 2011, Sanofi-Aventis changed their name to Sanofi. Today, Sanofi has grown to become a multinational company which focuses on a variety of therapeutic areas including the cardiovascular system, diabetes, oncology, and the central nervous system.
Sanofi Drug Info
Clomid, sold under the brand name Serophene, has been marketed and sold since 1967 when it was first approved by the Federal Drug Administration. Clomid is an ovulatory stimulation medication and is used to increase egg production in women. Doctors have also prescribed Clomid for several off-label treatments, especially for hypogonadism. Unfortunately, without appropriate testing and FDA approval, the prescribing of medications for this purpose may cause unknown side-effects. The FDA has also indicated there have been reports of visual symptoms associated with taking this medication, including blurred visition. Patients also report ovarian enlargement during or shortly after therapy with Clomid as well as an increased chance of multiple pregnancies. The FDA also reports that “birth anomalies spontaneously reported as individual cases since commercial availability of Clomid, the proportion of neural tube defects has been high among pregnancies associated with ovulation induced by Clomid, but this has not been supported by data from population-based studies.” The CDC has also studied Clomid and has reported that it may increase the risk of birth defects. According to a study that was published in the 2010 medical journal entitled Human Reproduction, it is suggested that the use of Clomid may increase the risk of birth defects including anencephaly, septal heart defects, coarctation of the aorta, esophageal atresia, craniosynostosis, or omphalocele. With this in mind, the FDA has assigned Clomid to the highest pregnancy risk category- Category X.
More Sanofi Drugs
Given the severity of some of the birth defects some of the mothers who have taken Clomid have filed lawsuits against the medication’s manufacturers, laboratories, sales representatives, the pharmacist, the prescribing physician, or a medical facility. Claimants who successfully win their Clomid lawsuit may be entitled to compensation for their medical bills, prescription costs, lost wages, and pain and suffering. Unfortunately, winning a lawsuit will not restore the health of your child, but it may allow you to get better medical treatment for their health conditions. Although for many women Clomid is a successful therapy to stimulate egg production, some children who have been exposed to Clomid in utero have been born with severe health conditions. Clomid should not be used if a woman is pregnant, if they have abnormal vaginal bleeding, or they have abnormal liver function. Women should also be evaluated for ovarian and primary pituitary function, endometriosis, endometrial carcinoma, thyroid disorders, adrenal disorders, and hyperprolactinemia prior to the use of Clomid.